Our history

YEAREVENT
2017
  • In February, PBKM obtains approval from the US Food and Drug Administration (FDA) to deliver stem cells for treatments to american clinics
  • PBKM starts operations in Sweden and England
  • The number of patients that recieved stem cells produced in the laboratory of PBKM laboratory has exceeded 1000.
  • In July, PBKM won the InnoNeuroPharm competition and received a National Research and Development grant for development of use of stem cells in treating ALS (Alzheimer's Side Sclerosis)
2016
  • In April, for the first time, the stock of PBKM is offered to the public on Warsaw Stock Exchange.
  • PBKM is the first family blood bank to become a member of the prestigious European Group for Bone Marrow Transplantation (EBMT)
2015
  • The number of umbilical cord blood transplants stored by the Famicord Group reaches 20, while the number of patients treated with advanced therapy products is over 100.
  • Confirmed selection of PBKM consortia with the Jagiellonian University, the Silesian Medical University and the AGH University of Science and Technology, and the Warsaw Medical University and the Warsaw University to conduct three research and development projects financed by the Strategmed II project.
  • The number of families banking cord blood in Famicord Group's exceeds 122,000 samples of cord blood  tissue.
  • Obtaining another accreditation from the American Association of Blood Banks (AABB)
2014
  • Obtaining permissions of The Main Pharmaceutical Inspector in Poland for preparation of Advanced therapy Medicinal Products ( ATMP) derived from umbilical cord, bone marrow, cord blood, adipose tissue and mobilized peripheral blood.
  • Establishing cooperation with several Polish medical centers to start experimental therapies in the area of neurology and hematology using ATMP products,
  • Acquisition of 100% of shares in Diagnostics Bank Stem Cells.
  • Joint venture with the University of Warmia and Mazury in Olsztyn and a private investor, Institute of Cell Therapies S.A.
  • Acquisition of customers of umbilical cord blood banks at the Oncology Center in Warsaw
2013
  • Launch of Warsaw's largest and most modern laboratory for umbilical cord blood in Warsaw.
    The Chief Pharmaceutical Inspector (GIF) issues the sole consent in Poland for PBKM to produce a mesenchymal Wharton jelly cell.
  • Another (winning the Ministry of Health competition for running a public stem cell bank within the framework of the National Program for the Development of Transplant Medicine.
  • Total acquisition of Biogenis and Stemlab Diagnostic in Romania
  • Acquisition in Turkey (Yasam Bankasi) and Poland (Longa Vita Sp. Z oo)
2012
  • The Ministry of Health re-accredits PBKM for the processing and storage of stem cells from umbilical cord blood. Accreditation is valid for 5 years.
  • Achieve over 65,000 stored stem or tissue samples by the Group.
  • Conducting the first transplant of stem cells from umbilical cord blood stored by the Group in Turkey.
  • Acquisition of control over foreign companies: Sevibe Cells (Spain) and Famicord Italia, acquisition of 100% shares of Polish company Cryoprofil, acquisition of shares in Stemlab (Romania) and indirect acquisition of the new Famicord Hungary by Krio Institute.
2011
  • The first treatment in Poland using mesenchymal stem cells
  • Aproval of the Ministry of Health competition for running a public stem cell bank within the framework of the National Program for Transplantation Medicine Development.
  • Further transplantation of stem cells from umbilical cord blood
2010
  • Conducting the first cord blood stem cell transplant in Hungary kept in the Group.
  • Lloyds Registry certification of ISO 9001: 2008 certified laboratories
2009
  • Conducting the first cord blood stem cell transplant in Hungary kept in the Group.
    Lloyds Registry certification of ISO 9001: 2008 certified laboratories
2008
  • Purchase of shares in Krio Intezet in Hungary, joint venture of Sevibe Cells in Spain and acquisition of part of Activision Life S.A.
  • The second edition in Poland for transplantation of umbilical cord blood stem cells stored in PBKM.
  • The transplant took place at the Cathedral
    And the Department of Pediatrics, Hematology and Oncology, Collegium of Nicolaus Copernicus University in Bydgoszcz.
    Third in PBKM and first autologous transplantation of umbilical cord blood stem cells stored in PBKM.
2007
  • Another expansion of the lab in the Children's Health Center.
  • Opening of a FamiCord- Famicord Italia company in Italy.
2006
  • Purchase of shares in Krio Intezet in Hungary, joint venture of Sevibe Cells in Spain and acquisition of part of Activision Life S.A.
  • The second edition in Poland for transplantation of umbilical cord blood stem cells stored in PBKM. The transplant took place at the Cathedral
  • And the Department of Pediatrics, Hematology and Oncology, Collegium of Nicolaus Copernicus University in Bydgoszcz.
  • Third in PBKM and first autologous transplantation of umbilical cord blood stem cells stored in PBKM.
2005
  • Establishment of the Non-Public Healthcare Facility "Polish Bank of Stem Cells" with its seat in the Children's Health Center, which consists of two organizational units: umbilical cord blood bank and medical diagnostic laboratory.
  • Achieving a leading position in the Polish market and increasing its reach across Poland.
2004
  • Lloyds Registry acknowledges  ISO 9001: 2000 quality management certificate for collection, preparation, freezing and storage of stem cells
2003
  • PBKM as the only umbilical cord blood bank in Poland has been subjected to external audits by the National Blood Center and Blood Donors Center for compliance with standards, regulations and procedures.
  • Beginning of partnership with a stem cell bank in the United States, based on which PH.D  Zbigniew Roger Mrowiec, Director of the laboratory of  Community Blood Service in  New Jersey, joined the Scientific Board of PBKM.
2002
  • Establishment of PBKM (Polski Bank Komórkek Macierzstych). Business idea was inspired by the growing interest in therapeutic use of stem cells all over the world.
  • Creation of own laboratory in Centrum Zdrowia Dziecka w Warszawie ( Children's Health Center in Warsaw)